Human Antibodies & Hybridomas

April 2022, The Richard Doll Building, University of Oxford, Oxford, UK

  • Increase font size
  • Default font size
  • Decrease font size


Due to the current COVID-19 crisis, HAH 2022 has been postponed from 11-13 November 2020 to April 2022.

Join the conversation on Twitter – #HAH2022

Sponsored by the International Journal Human Antibodies
In association with the Integrative Medical Sciences Association

The HAH 2022 scientific programme will have a broadened scope from previous events with the addition of some new topic areas outlined in the scope section below. As usual the scientific programme will include keynote lectures, contributed oral papers and poster presentations emphasising all key aspects of human antibody technologies, applications and engineering.

Scientific Advisory Panel

Programme Chairman: Professor Mark Glassy (UCSD Moores Cancer Center, San Diego, California, USA)

Chris Scott (The Queen’s University, Belfast, Northern Ireland, UK)
Jim Larrick (Panorama Research Inc., USA)
Alois Lang (GeNeuro SA, Geneva, Switzerland)David P. Humphreys (UCB, Slough, UK)
Markus Enzelberger (MorphoSys AG, Martinsried, Germany)
Eszter Nagy (Arsanis GmbH, Vienna, Austria)
Sachdev Sidhu (University of Toronto, Canada)
Neil Brewis (F-star, Cambridge, UK)
Paul Kerr (Fusion Antibodies, Belfast, Northern Ireland, UK)
David Naor (The Hebrew University, Jerusalem, Israel)
Lynn MacDonald (Regeneron Pharmaceuticals, Tarrytown, New York, USA)
Maria Groves (Medimmune, Cambridge, UK)
Hermann Katinger and Dietmar Katinger (Polymun Scientific Immunbiologische Forschung GmbH, Vienna, Austria)
Andrew T. Serafini (Kilpatrick Townsend, Seattle, Washington, USA)
Rick Buick (Fusion Antibodies, Belfast, Northern Ireland, UK)
Mohamed Taheri (Beheshti University of Medical sciences, Tehran, Iran)

Conference Scope

The scope of the HAH 2022 conference falls broadly the following main session categories:

  • Infectious Diseases
  • Autoimmunity
  • Molecular Biology
  • Emerging Technologies Clinical Applications
  • Therapeutic Antibodies
  • Cancer
  • Anti-Infective Antibodies
  • Intellectual Property & Legal Issues

For this and future meetings the scope is being expanded to include sessions on:

  • Formulation
  • Oral Delivery
  • Combination Therapy
  • Validity of Animal Models
  • Peptide Drugs
  • Immunotherapy of Cancer & Autoimmunity

HAH 2022 will also have a special focus on Updates on Antibody-Drug Conjugates.

Invited Keynote Speaker: Paul Parren (Lava Therapeutics, Utrecht, The Netherlands)


HAH 2022 Delegates

Login details will be supplied after you have registered for the event.

HAH 2022 Sponsors

  • ADC Review
  • Polymun Scientific
  • University of California, Riverside
  • Kilpatrick Townsend
  • Merck
  • UCB
  • OncoZine
  • Nascent Biotech
  • F-star
  • Geneuro
  • Regeneron
  • Aldevron
  • Fusion Antibodies

HAH 2022 Mailing List

E-mail Address
What is 3+2-1?